Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-07-22
2009-10-27
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S428000
Reexamination Certificate
active
07608637
ABSTRACT:
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4agonist as an active ingredient. An EP4agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).
REFERENCES:
patent: 3975399 (1976-08-01), DeFranco et al.
patent: 4054736 (1977-10-01), Hayashi et al.
patent: 4113873 (1978-09-01), Himizu et al.
patent: 4115401 (1978-09-01), Nanthavong et al.
patent: 4177346 (1979-12-01), Nelson
patent: 4320136 (1982-03-01), Scribner
patent: 6156799 (2000-12-01), Hartke et al.
patent: 6211226 (2001-04-01), Hellberg et al.
patent: 6414006 (2002-07-01), Harada et al.
patent: 6462081 (2002-10-01), Maruyama et al.
patent: 6476074 (2002-11-01), Stjernschantz et al.
patent: 6552067 (2003-04-01), Cameron et al.
patent: 6586457 (2003-07-01), Harada et al.
patent: 6747054 (2004-06-01), Cameron et al.
patent: 6849657 (2005-02-01), Elworthy et al.
patent: 7192979 (2007-03-01), Cameron et al.
patent: 841165 (1976-10-01), None
patent: 1 121 939 (2001-08-01), None
patent: 1121939 (2001-08-01), None
patent: 1 132 086 (2001-09-01), None
patent: 11320867 (2001-09-01), None
patent: 1 232 757 (2002-08-01), None
patent: 1 110 949 (2003-09-01), None
patent: 1553595 (1979-10-01), None
patent: 1569982 (1980-06-01), None
patent: 1583163 (1981-01-01), None
patent: 2330307 (1999-04-01), None
patent: 99/02164 (1999-01-01), None
patent: WO 99/12551 (1999-03-01), None
patent: WO 00/03980 (2000-01-01), None
patent: 00/21532 (2000-04-01), None
patent: 00/21542 (2000-04-01), None
patent: WO 01/46140 (2001-07-01), None
patent: 01/62724 (2001-08-01), None
patent: 02/24647 (2002-03-01), None
patent: 02/42268 (2002-05-01), None
International Search Report dated Oct. 10, 2002.
Taiwanese Office Action.
Zoretic, P. A. et al., Synthesis of (E)-74-[[2-[4-(m-trifluoromethylphenoxy)-3α and 3β-Hydroxy-1-butenyl]-5-oxo-1-pyrrolidinyl]]heptanoic Acids, Department of Chemistry, J. Heterocyclic Chem., 20, 465 (1983).
Ono, K. et al., Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2, Journal of Endocrinology 158, R1-R5, 1998.
Shigeyoshi Saijo et al., Heterocyclic Prostaglandins IV1)Synthesis of 8-Aza-1 E1and Its Related Compounds, Organic Chemistry Research Laboratory, Aug. 10, 1979.
Suzawa, Tetsuo et al., The Role of Prostaglandin E Receptor Subtypes (EP1, EP2, EP3, and EP4) in Bond Resorption: An Analysis Using Specific Agonists for the Respective EPs, Department of Biochemistry, Endocrinology, vol. 141, No. 4 (2000).
Suda, M. et al., Prostaglandin E Receptor Subtypes in Mouse Osteoblastic Cell Line, Departments of Medicine and Clinical Science, Radiology and Nuclear Medicine and Pharmacology, Endocrinology, vol. 137, No. 5 (1996).
Hazato, Atsuo et al., Synthesis of Thiaprostaglandin E1Derivatives1).Institute for Bio-medical Research, Chem. Pharm. Bull. 33(5)1815-1825 (1985).
Maruyama Takayuki
Maruyama Toru
Marschel Ardin
Ono Pharmaceutical Co. Ltd.
Royds Leslie A
Sughrue & Mion, PLLC
LandOfFree
Pharmaceutical composition for treatment of diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for treatment of diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for treatment of diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4092244